Retatrutide Dosage in Published Trials

What the published trials administered

Retatrutide has a half-life of roughly six days, and the published trial programme administered it once weekly. In the Phase-2 trial reported in the New England Journal of Medicine (2023), investigators escalated the weekly amount gradually across the study rather than beginning at the highest level, with the highest study arm reaching approximately 12 mg per week.

Why the protocols escalated gradually

The adverse events most frequently reported for this class — nausea, reduced appetite and gastrointestinal upset — are described in the trial literature as dose-dependent. Published protocols therefore began at a low weekly amount and increased in steps. This records how the studies were designed; it is not guidance.

Regulatory status

Retatrutide is investigational. It has not been evaluated or approved by the European Medicines Agency, the FDA or any other regulatory authority, and no approved dosing exists for it in any jurisdiction. See is retatrutide FDA approved? for the trial-stage detail.

Concentration arithmetic for laboratory work

For bench work what matters is concentration rather than any administered amount: a 10 mg vial reconstituted in 2 mL gives 5 mg/mL. The reconstitution calculator performs that arithmetic for the figures you enter — it does not recommend an amount. If units on a graduated syringe are unfamiliar, see measuring small volumes.